| Drug Name |
Aclidinium bromide |
| Drug ID |
BADD_D00037 |
| Description |
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. |
| Indications and Usage |
Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. |
| Marketing Status |
Prescription |
| ATC Code |
R03BB05 |
| DrugBank ID |
DB08897
|
| KEGG ID |
D08837
|
| MeSH ID |
C542859
|
| PubChem ID |
11519741
|
| TTD Drug ID |
D07KHH
|
| NDC Product Code |
54893-0027; 64567-0028; 72124-002; 0310-0800 |
| Synonyms |
aclidinium bromide | (3R)-3-((hydroxy(di-2-thienyl)acetyl)oxy)-1-(3-phenoxypropyl)-1-azoniabicyclo(2.2.2)octane bromide |
